Your browser doesn't support javascript.
loading
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk, Aline; George, Joshy; Wang, Chen; Budden, Timothy; Tan, Tuan Zea; Chiu, Derek S; Kommoss, Stefan; Leong, Huei San; Chen, Stephanie; Intermaggio, Maria P; Gilks, Blake; Nazeran, Tayyebeh M; Volchek, Mila; Elatre, Wafaa; Bentley, Rex C; Senz, Janine; Lum, Amy; Chow, Veronica; Sudderuddin, Hanwei; Mackenzie, Robertson; Leong, Samuel C Y; Liu, Geyi; Johnson, Dustin; Chen, Billy; Group, Aocs; Alsop, Jennifer; Banerjee, Susana N; Behrens, Sabine; Bodelon, Clara; Brand, Alison H; Brinton, Louise; Carney, Michael E; Chiew, Yoke-Eng; Cushing-Haugen, Kara L; Cybulski, Cezary; Ennis, Darren; Fereday, Sian; Fortner, Renée T; García-Donas, Jesús; Gentry-Maharaj, Aleksandra; Glasspool, Rosalind; Goranova, Teodora; Greene, Casey S; Haluska, Paul; Harris, Holly R; Hendley, Joy; Hernandez, Brenda Y; Herpel, Esther; Jimenez-Linan, Mercedes; Karpinskyj, Chloe.
Affiliation
  • Talhouk A; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • George J; University of British Columbia, Department of Obstetrics and Gynecology, Vancouver, British Columbia, Canada.
  • Wang C; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Budden T; Mayo Clinic, Division of Biomedical Statistics and Informatics, Department of Health Science Research, Rochester, Minnesota.
  • Tan TZ; University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, New South Wales, Australia.
  • Chiu DS; The University of Manchester, CRUK Manchester Institute, Manchester, United Kingdom.
  • Kommoss S; National University of Singapore, Cancer Science Institute of Singapore, Center for Translational Medicine, Singapore, Singapore.
  • Leong HS; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Chen S; Tuebingen University Hospital, Department of Women's Health, Tuebingen, Germany.
  • Intermaggio MP; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
  • Gilks B; Cedars-Sinai Medical Center, Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California.
  • Nazeran TM; University of NSW Sydney, School of Women's and Children's Health, Faculty of Medicine, Sydney, New South Wales, Australia.
  • Volchek M; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Elatre W; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Bentley RC; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Senz J; Royal Women's Hospital, Anatomical Pathology, Parkville, Victoria, Australia.
  • Lum A; Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Chow V; Department of Pathology, Duke University Hospital, Durham, North Carolina.
  • Sudderuddin H; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Mackenzie R; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Leong SCY; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Liu G; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Johnson D; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Chen B; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Group A; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Alsop J; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Banerjee SN; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Behrens S; British Columbia's Gynecological Cancer Research Program (OVCARE), BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, British Columbia, Canada.
  • Bodelon C; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
  • Brand AH; QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane, Queensland, Australia.
  • Brinton L; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
  • Carney ME; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Chiew YE; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Gynaecology Unit, London, United Kingdom.
  • Cushing-Haugen KL; German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
  • Cybulski C; NCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
  • Ennis D; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Fereday S; NCI, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
  • Fortner RT; Department of Obstetrics and Gynecology, University of Hawaii, John A. Burns School of Medicine, Honolulu, Hawaii.
  • García-Donas J; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, New South Wales, Australia.
  • Gentry-Maharaj A; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Glasspool R; Fred Hutchinson Cancer Research Center, Program in Epidemiology, Division of Public Health Sciences, Seattle, Washington.
  • Goranova T; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Greene CS; Imperial College London, Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, London, United Kingdom.
  • Haluska P; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Harris HR; Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
  • Hendley J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Hernandez BY; German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
  • Herpel E; HM Hospitales Centro Integral Oncológico Clara Campal (HM CIOCC), Madrid, Spain.
  • Jimenez-Linan M; University College London, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, London, United Kingdom.
  • Karpinskyj C; Department of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom.
Clin Cancer Res ; 26(20): 5411-5423, 2020 10 15.
Article in En | MEDLINE | ID: mdl-32554541
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenoma, Serous / Transcriptome / Neoplasm Proteins Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2020 Type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Cystadenoma, Serous / Transcriptome / Neoplasm Proteins Type of study: Guideline / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2020 Type: Article Affiliation country: Canada